An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB .

A pioneering study presented today at ESCMID Global 2025 has demonstrated that an AI-powered lung ultrasound outperforms human experts by 9% in diagnosing pulmonary tuberculosis (TB).

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB ... based on mouse-model research of the lung-damaging disease. Findings ...

A study has shown that an AI-powered lung ultrasound outperforms human experts by 9% in diagnosing pulmonary tuberculosis ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, investigators ...

A study presented at ESCMID Global 2025 has demonstrated that an AI-powered lung ultrasound outperforms human experts by 9% ...

In a Johns Hopkins Children’s Center study, the addition of navitoclax to the standard TB treatment significantly increased ...

A pioneering study presented today at ESCMID Global 2025 has demonstrated that an AI-powered lung ultrasound outperforms human experts by 9% in diagnosing pulmonary tuberculosis (TB).1 ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis ... based on mouse-model research of the lung-damaging disease.

TB is caused by Mycobacterium tuberculosis, a type of bacterial species. In early stages, infected lung cells limit spread through apoptosis, a natural and tightly regulated molecular process that ...